Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma (NAMS) Total Debt (2022 - 2025)

NewAmsterdam Pharma's Total Debt history spans 4 years, with the latest figure at $57.3 million for Q4 2025.

  • For Q4 2025, Total Debt rose 52.67% year-over-year to $57.3 million; the TTM value through Dec 2025 reached $57.3 million, up 52.67%, while the annual FY2025 figure was $57.3 million, 52.67% up from the prior year.
  • Total Debt for Q4 2025 was $57.3 million at NewAmsterdam Pharma, up from $44.4 million in the prior quarter.
  • Across five years, Total Debt topped out at $57.3 million in Q4 2025 and bottomed at $4.1 million in Q4 2022.
  • The 4-year median for Total Debt is $23.5 million (2024), against an average of $27.6 million.
  • The largest annual shift saw Total Debt soared 203.21% in 2023 before it fell 28.85% in 2025.
  • A 4-year view of Total Debt shows it stood at $4.1 million in 2022, then skyrocketed by 203.21% to $12.6 million in 2023, then skyrocketed by 198.35% to $37.5 million in 2024, then soared by 52.67% to $57.3 million in 2025.
  • Per Business Quant, the three most recent readings for NAMS's Total Debt are $57.3 million (Q4 2025), $44.4 million (Q3 2025), and $20.9 million (Q2 2025).